Neuroscience
From The New York Times:
-
Anthony H. Risser | neuroscience | neuropsychology | brain
- Fda: Pcns Drugs Advisory Committee Results For Avid's Amyvid Alzheimer's Amyloid Neuroimaging Agent
From The New York Times: F.D.A. Sees Promise in Alzheimer’s Imaging Drug By THE ASSOCIATED PRESS Published: January 20, 2011 Filed at 5:40 p.m. ESTWASHINGTON (AP) — A federal panel of medical experts said Thursday a first-of-a-kind imaging chemical...
- Daytrana (methylphenidate Patch) & Adhd
From the website of The Washington Post: FDA OKs First Attention Deficit Patch By ANDREW BRIDGES The Associated Press Thursday, April 6, 2006; 8:06 PM WASHINGTON -- The FDA on Thursday approved the first skin patch to treat attention deficit hyperactivity...
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab) And Ms
From the AP, via the New York Times website: FDA Panel Supports MS Drug's Market Return By THE ASSOCIATED PRESS Published: March 8, 2006 Filed at 11:24 a.m. ET WASHINGTON (AP) -- A Food and Drug Administration panel said Wednesday the agency should...
- Methylphenidate Transdermal Patch (daytrana), Adhd, & The Fda: Thursday And Friday
THURSDAY: From The Washington Post website:Problem Found With Potential ADHD Patch The Associated Press Thursday, December 1, 2005; 3:01 PM WASHINGTON -- A patch developed to treat attention deficit hyperactivity disorder in children received a negative...
- Adhd Treatment
The full-text contents of the following article is available on the Pediatrics website at this link [Click here]: Ronald T. Brown, Robert W. Amler, Wendy S. Freeman, James M. Perrin, Martin T. Stein, Heidi M. Feldman, Karen Pierce, Mark L. Wolraich and...
Neuroscience
Methylphenidate
From The New York Times:
Panel Recommends Warnings for Ritalin and Other Stimulants[ ... Read the full article ... ]
By THE ASSOCIATED PRESS
Published: February 9, 2006
Filed at 4:13 p.m. ET
WASHINGTON (AP) -- Federal science advisers voted narrowly Thursday to recommend the most serious type of warning labels for Ritalin and other stimulants that are used to treat attention deficit hyperactivity disorder.
The 8-7 vote, with one abstention, by the Food and Drug Administration committee was to recommend adding ''black box'' safety warnings to ADHD drugs. Doctors prescribe the increasingly popular drugs to about 2 million children and 1 million adults a month.
The FDA isn't required to follow the recommendations of its advisory committees but typically does.
[...continues...]
-
Anthony H. Risser | neuroscience | neuropsychology | brain
- Fda: Pcns Drugs Advisory Committee Results For Avid's Amyvid Alzheimer's Amyloid Neuroimaging Agent
From The New York Times: F.D.A. Sees Promise in Alzheimer’s Imaging Drug By THE ASSOCIATED PRESS Published: January 20, 2011 Filed at 5:40 p.m. ESTWASHINGTON (AP) — A federal panel of medical experts said Thursday a first-of-a-kind imaging chemical...
- Daytrana (methylphenidate Patch) & Adhd
From the website of The Washington Post: FDA OKs First Attention Deficit Patch By ANDREW BRIDGES The Associated Press Thursday, April 6, 2006; 8:06 PM WASHINGTON -- The FDA on Thursday approved the first skin patch to treat attention deficit hyperactivity...
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab) And Ms
From the AP, via the New York Times website: FDA Panel Supports MS Drug's Market Return By THE ASSOCIATED PRESS Published: March 8, 2006 Filed at 11:24 a.m. ET WASHINGTON (AP) -- A Food and Drug Administration panel said Wednesday the agency should...
- Methylphenidate Transdermal Patch (daytrana), Adhd, & The Fda: Thursday And Friday
THURSDAY: From The Washington Post website:Problem Found With Potential ADHD Patch The Associated Press Thursday, December 1, 2005; 3:01 PM WASHINGTON -- A patch developed to treat attention deficit hyperactivity disorder in children received a negative...
- Adhd Treatment
The full-text contents of the following article is available on the Pediatrics website at this link [Click here]: Ronald T. Brown, Robert W. Amler, Wendy S. Freeman, James M. Perrin, Martin T. Stein, Heidi M. Feldman, Karen Pierce, Mark L. Wolraich and...